NINA CHARBONNEAU: Open Payments
NPI 1740021807 · TROY, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,255 in 47 payments from 17 companies in 2025. Trend: 2023 $0 · 2024 $148 · 2025 $1,255
Food & beverage: $1,255
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 10 | $285 |
| AstraZeneca Pharmaceuticals LP | 3 | $157 |
| Ferring Pharmaceuticals Inc. | 5 | $127 |
| Endo USA, Inc. | 4 | $95 |
| Janssen Biotech, Inc. | 3 | $85 |
| ABBVIE INC. | 3 | $82 |
| Antares Pharma, Inc. | 4 | $75 |
| Alnylam Pharmaceuticals Inc. | 3 | $58 |
| UROGEN PHARMA, INC. | 1 | $43 |
| Merck Sharp & Dohme LLC | 2 | $42 |
Products named: GEMTESA, AIRSUPRA, ADSTILADRIN, ERLEADA, BOTOX, XYOSTED, XTANDI, GIVLAARI.
Industry payments across NY — which companies pay providers there.
